

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6.: A61K 31/57, 31/565	A1	(11) International Publication Number: WO 95/07081 (43) International Publication Date: 16 March 1995 (16.03.95)
(21) International Application Number: PCT/EP94/02997 (22) International Filing Date: 8 September 1994 (08.09.94) (30) Priority Data: 9301562 9 September 1993 (09.09.93) NL (71) Applicant (for all designated States except US): SATURNUS AG [LU/LU]; 11, rue Aldringen, L-2960 Luxemburg (LU). (72) Inventor; and (75) Inventor/Applicant (for US only): KONINCKX, Philippe, Robert, Marie, Wilhelmus, Ghislain [BE/BE]; Vuilenbos 2, B-3360 Bierbeek (BE). (74) Agent: PRINS, Hendrik, Willem; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).	(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: PREPARATION FOR SUBSTITUTION THERAPY, CONTAINING AT LEAST ONE PROGESTOGEN AND AT LEAST ONE ESTROGEN (57) Abstract The invention relates to a preparation for substitution therapy and oral contraception comprising at least one progestogen and at least one estrogen in which the estrogen dose varies with a periodicity such that blood loss is substantially avoided, wherein the periodicity is preferably less than 10 days, more preferably less than 7 days, such as preparations containing the progestogen and/or estrogen in an oral, transdermal, parenteral and/or implantable application form.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PREPARATION FOR SUBSTITUTION THERAPY, CONTAINING AT LEAST ONE PROGESTOGEN AND AT LEAST ONE ESTROGEN.

The present invention relates to a preparation for substitution therapy and for oral contraception. More particularly the present invention on the one hand relates to relieving the effects which occur because the ovaries decrease or stop production of female hormones, for instance during the menopause. The substitution therapy is mainly intended to induce amenorrhoea with negligible blood loss.

During and after the menopause these effects comprise hot flushes and nocturnal sweating, atrophy of the vagina which can result in sexual difficulties, bone decalcification, increase in heart and blood vessel disorders and psychic symptoms with a causal connection that is usually difficult to demonstrate.

Up to the present different types of substitution therapy have been applied comprising a hormone treatment with one or more oestrogens and one or more progestogens.

According to a first therapy, low doses of oestrogens and progestogens are administered, but such a treatment is ineffective in respect of the decalcification and heart and blood vessel disorders.

In another therapy the natural cycle of oestrogen and progestogen is followed as closely as possible. This treatment inevitably results in menstruation and has the advantage of a reduced risk of cancer of the uterus.

According to yet another therapy only oestrogens are administered in a dose which lies below the threshold for menstrual bleeding. This treatment has the drawback however of an increased risk of cancer of the uterus.

According to a most recently known therapy oestrogens and progestogens are administered continuously, such that the endometrium does not proliferate. This therapy has the drawback however of an unacceptably high incidence of slight, irregular blood loss.

CONFIRMATION COPY

The present invention has for its object to provide a substitution therapy wherein the above described drawbacks occur to a much lesser extent, with the objective of inducing amenorrhoea with negligible blood loss over a long period (many months to years).

On the other hand, the present invention relates to preparations designed for oral contraception with substantially continuous application.

In continuous application of oral contraceptive frequently intermediate bleedings occur. The preparations according to the present invention are designed to induce menstrual bleeding with a regular menstrual bleeding, with an extended cycle or eventually a constant amenorrhoea, but characterized by an optimal (cycle) control and/or by a substantially reduced occurrence of intermediate bleeding.

EP-A-559 240 discloses preparations for substitution therapy and oral contraception in which the estrogen dose is constant and the progestagen dose is periodically alternated.

However, the improvement in inhibiting endometrium bleeding is minor. Above that, since the use of higher progestagen doses provided better results than lower doses it appears illogical to use periodically varying estrogen doses.

The present invention is based on the finding that surprisingly when using periodically varying estrogen doses the occurrence of blood loss and intermediate bleeding is substantially avoided. The estrogen dose is herein oscillated such that estrogen-dominant and progestogen-dominant periods occur alternately with a sufficiently short periodicity. This short periodicity in the estrogen dose is necessary to avoid blood loss.

Purely by administering a dose of progestogen or estrogen substantially constant in time and an estrogen or progestogen varying in time between at least two dose levels, it was possible to induce the desired amenorrhoea while no blood loss occurred over a longer period.

The invention therefore relates to a preparation for substitution therapy and for oral contraception comprising at least one progestogen and at least one estrogen in which the

estrogen dose varies with a periodicity such that blood loss is substantially avoided.

It is noted that the preparation is formulated such that a substantially constant blood concentration is obtained for progestogen or estrogen, while the estrogen concentration in the blood varies between two blood concentrations. The periodicity must be sufficiently short and is generally less than 10 days. The periodicity is usually less than 7 days. The periodicity generally lies between 2-9 days, preferably between 2-6 days. It will however be apparent that the periodicity is dependent on the estrogens and progestogens used and the applied doses. Both the periodicity and concentrations of estrogen and progestogen are easy to determine by routine experimentation.

According to an embodiment of the invention the preparation contains a constant progestogen dose, while the estrogen dose oscillates between two levels. This preparation is recommended because there is a greater certainty of avoiding blood loss over a longer period.

According to another embodiment the preparation contains oscillating doses of progestogen and estrogen, in varying ratios however such that blood loss is avoided and amenorrhoea is induced.

Use can be made in general of all known progestogens, such as

	progesterone	300-900 mg/day
	norethisterone acetate	2-5 mg/day
	medroxyprogesterone acetate	1-5 mg/day
	d-norgestrel	30-150 µgr/day
30	desogestrel	30-150 µgr/day
	norgestimate	30-150 µgr/day
	cyproterone acetate	0.2-2 mg/day,
	gestodene	10-150 µg/day
	3-ketodesogestrel	10-150 µg/day
35	drospirenon	0.2-3.0 mg/day

or combinations thereof. It is noted that the preparation can contain one or more progestogens and estrogens.

It will be apparent that the quantity of progestogen and estrogen depends on the person (constitution and age),

the progestogen(s) and estrogen(s), anti-progestogen and anti-estrogen for use and the form of administering same.

The progestogen and estrogen can each be present in an oral, transdermal, parenteral or implantable application form for substitution therapy. The preparation can for instance comprise an application form which contains the progestogen and estrogen, and a second like application form which contains the progestogen and an increased dose of estrogen. The progestogen and estrogen can of course be present in like but separate forms of application or in mutually differing forms of application. The progestogen can for instance be an implantable application form while the oestrogen is administered orally, transdermally or parenterally in a dose which takes account of the required time period according to the invention.

The oral application form to be used comprises tablets, capsules, syrup, solutions. The transdermal forms of application comprise gels, plasters. Strips can for instance be used wherein tablets with progestogen and oestrogen in the desired ratio and periodicity are arranged in time sequence. The parenteral application form comprises injection fluid and the like. The implantable application form comprises for example a known implantable sustained release preparation.

The preparations for oral contraceptive comprise estrogens and progestogens in common form.

Preparations according to the invention were administered over a period of 3-12 months to 40 women in the menopause. By making use of the combination preparations according to the invention a constant amenorrhoea could be obtained in the case of more than 90% of the women, wherein the clinical tolerance was perceived as optimal, wherein the woman did not discern any subjective difference between a fixed or changing oestrogen dose with a periodicity of about one week.

Using the preparations according to the invention as oral contraceptive intermediate bleeding will be substantially reduced.

Example 1

A preparation according to the invention comprised tablets of the type A which contained 10 gamma aethinyl-estradiol, 1 mg estradiol valerianate and 0.5 mg norethisterone, and tablets of the type B which contained 15 gamma instead of 10 gamma aethinyl-estradiol. By alternately administering the tablets A and B over a time period of 7 days an amenorrhoea could be induced without blood loss for a very long period of time.

10 Example 2

A preparation according to the invention contained 1 mg norethisterone or 0.5 mg cyproterone acetate and 2 mg estradiol valerianate. The preparation moreover contained tablets of the type B having 3 mg instead of 2 mg estradiol valerianate. By using the preparation with alternate administering (4-5 days) of the tablets A and B or B and A an amenorrhoea could be induced without blood loss for a longer period of time.

Example 3

20 A preparation according to the invention comprised tablets of the type A which contained 15 gamma aethinyl-estradiol and 1 mg oestradiol valerianate and 1 mg norethisterone. The preparation moreover contained tablets of the type B having 1.5 mg instead of 1 mg norethisterone. By 25 alternately administering the tablets A and B with a periodicity of 4-7 days an amenorrhoea could be induced without blood loss for a very long period of time.

Example 4

A preparation according to the invention for oral contraceptive with optimal cycle control comprises tablets of type A comprising 20 µg aethinyl-estradiol and 75 µg gestoden. The preparation contained tablets of type B comprising 30 µg instead of 20 µg aethinyl-estradiol. Tablets A and B are used in four alternating periods of six days.

Example 5

A preparation according to the invention for oral contraceptive with optimal cycle control comprises tablets of type A comprising 15 µg aethinyl-estradiol and 75 µg gestoden, and tablets of type B comprising 25 µg instead of 15 µg aethinyl-estradiol. Tablets A and B are used in six alternating periods of four days.

In example 4 and 5 only aethinyl-estradiol is used in order to use a estrogen dose which is as low as possible. However, higher estrogen doses may be used. Instead of using a constant progestogen dose fluctuating doses may be use fluctuating simultaneously and/or progressively in view of the varying estrogen dose.

Example 6

A preparation for oral contraceptive according to the invention comprises tablets of type A comprising 20 µg aethinyl-estradiol and 75 µg gestoden, and tablets of type B comprising 30 µg aethinyl-estradiol and 75 µg gestoden and 50 µg onapristone. The tablets A and B are used in four alternating periods of each six days. After four periods the whole cycle is repeated without allowing a free period.

Example 7

A preparation according to the invention for hormone substitution treatment comprises tablets of type A comprising 2 µg estradiol valerianate and 50 µg gestoden. The tablets of type B comprised 3 µg estradiol valerianate and 25-100 µg onapristone. By alternatingly administering the tablets A and B over a time period of seven days amenorrhoea could be induced without blood loss for a very long period of time.

It is obvious for a skilled person in the examples in association with intermittently given antiprogestogen or anti-estrogen can be alternated alone or simultaneous with estrogens and/or progestagens. For instance, the antiprogestagen is added in a constant dose to the actual and the above mentioned combinations of estrogens and

progestagens in products for hormone replacement therapy and
for contraception.

CLAIMS

1. Preparation for substitution therapy and for oral contraception comprising at least one progestogen and at least one estrogen in which the estrogen dose varies with a periodicity such that blood loss is substantially avoided.
- 5 2. Preparation as claimed in claim 1, wherein the periodicity is less than 10 days, preferably less than 7 days.
3. Preparation as claimed in claim 1 or 2, wherein the periodicity amounts to 2-9 days, preferably 2-6 days.
- 10 4. Preparation as claimed in claims 1-3, wherein the dose of progestogen is substantially constant and the dose of oestrogen oscillates.
5. Preparation as claimed in claims 1-3, wherein the dose of progestogen and the dose of estrogen oscillate in
- 15 such a dose ratio, that blood loss is substantially avoided.
6. Preparation as claimed in claims 1-5, wherein the progestogen comprises

progesterone	300-900 mg/day
norethisterone acetate	0.2-5 mg/day
20 medroxyprogesterone acetate	1-5 mg/day
d-norgestrel	30-150 µg/day
desogestrel	30-150 µg/day
norgestimate	30-150 µg/day
cyproterone acetate	0.2-2 mg/day,
25 gestodene	10-150 µg/day
3-ketodesogestrel	10-150 µg/day
drospirenon	0.2-3.0 mg/day

 or combinations thereof.
7. Preparation as claimed in claims 1-6, wherein the
- 30 oestrogen comprises

aethinylestradiol	5-15 gamma/day
oestradiol valerianate	1-4 mg/day
oestradiol	1-2 mg/day
conjugated oestrogen	0.3-1.25 mg/day

oestriol 1-4 mg/day,
or combinations thereof.

8. Preparation as claimed in claims 1-7, comprising anti-progestogen.

5 9. Preparation as claimed in claim 1-8, comprising anti-estrogen.

10. Preparation as claimed in claims 1-9, containing the progestogen and/or estrogen in an oral, transdermal, parenteral and/or implantable application form.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 94/02997

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/57 A61K31/565

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 559 240 (JENCAP RESEARCH LIMITED) 8 September 1993 cited in the application see column 12, line 49 - column 14, line 44	1-7,10
A	EP,A,0 275 716 (RUTGERS, THE STATE UNIVERSITY) 27 July 1988 see claims 1,36	1-7,10
A	EP,A,0 279 977 (ALZA CORPORATION) 31 August 1988 see claims	1-7,10
A	EP,A,0 346 014 (IMPERIAL CHEMICAL INDUSTRIES PLC) 13 December 1989 see abstract	9

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

16 December 1994

Date of mailing of the international search report

04.01.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/EP 94/02997

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0559240	08-09-93	CA-A- 1332227	04-10-94
		CA-A- 1332228	04-10-94
		AU-B- 630334	29-10-92
		AU-A- 2276088	06-04-89
		AU-A- 3044892	11-02-93
		DE-D- 3888269	14-04-94
		DE-T- 3888269	07-07-94
		EP-A- 0309263	29-03-89
		JP-A- 1132523	25-05-89
		US-A- 5108995	28-04-92
		US-A- 5276022	04-01-94
		US-A- 5256421	26-10-93
EP-A-0275716	27-07-88	AU-A- 1242388	19-07-89
		WO-A- 8905663	29-06-89
		US-A- 4906169	06-03-90
		US-A- 5023084	11-06-91
		ZA-A- 8709729	23-06-88
EP-A-0279977	31-08-88	US-A- 4788062	29-11-88
		AU-A- 7998187	01-09-88
		JP-A- 63225318	20-09-88
		ZA-A- 8707420	14-04-88
EP-A-0346014	13-12-89	AT-T- 109351	15-08-94
		AU-B- 622184	02-04-92
		AU-A- 3592389	07-12-89
		DE-D- 68917219	08-09-94
		DE-T- 68917219	15-12-94
		ES-T- 2057124	16-10-94
		IL-A- 90410	31-07-94
		US-A- 5183814	02-02-93